{"id":20148,"date":"2024-07-29T07:48:13","date_gmt":"2024-07-29T05:48:13","guid":{"rendered":"https:\/\/www.m-q.ch\/?p=20148"},"modified":"2024-07-25T13:52:47","modified_gmt":"2024-07-25T11:52:47","slug":"amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick","status":"publish","type":"post","link":"https:\/\/www.m-q.ch\/de\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","title":{"rendered":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick"},"content":{"rendered":"
\"\"
Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)<\/figcaption><\/figure>\n

\u00dcber 50 t\u00f6dliche degenerative Krankheiten, darunter Alzheimer, Parkinson, Typ-II-Diabetes und viele seltene neurodegenerative Erkrankungen, sind mit der Fehlfaltung und Aggregation von Proteinen verbunden. Diese Krankheiten betreffen weltweit mehr als eine halbe Milliarde Menschen und fordern j\u00e4hrlich 3,6 Millionen Todesopfer, was die Gesellschaft rund USD 3 Milliarden pro Jahr kostet. Bislang gibt es keine wirksamen Behandlungen, die die fortschreitende Degeneration aufhalten oder umkehren k\u00f6nnten.\u00a0<\/p>\n

Amporin Pharmaceuticals hat sich zum Ziel gesetzt, eine neue Klasse von niedermolekularen Medikamenten zu entwickeln, die toxische l\u00f6sliche Oligomere und Poren in den Zellmembranen blockieren und beseitigen. Diese toxischen Substanzen reichern sich an und zerst\u00f6ren Zellen, indem sie L\u00f6cher in die Zellmembranen bohren, was zum Verlust der Hom\u00f6ostase und zu fortschreitender Degeneration f\u00fchrt. Das Unternehmen plant die Entwicklung und Lizenzierung der ersten wirksamen, akut oral einzunehmenden krankheitsmodifizierenden Behandlungen f\u00fcr bis zu sechs bedeutenden Krankheiten, darunter Alzheimer und Typ-II-Diabetes, mit anf\u00e4nglichem Schwerpunkt auf Parkinson und ALS (amyotrophe Lateralsklerose).<\/p>\n

Allein an Parkinson leiden etwa eine Million Menschen in den USA und weltweit rund zehn Millionen Menschen. Der derzeitig globale Arzneimittelmarkt f\u00fcr Parkinson bel\u00e4uft sich auf etwa USD 6 Milliarden pro Jahr, mit einem potenziellen Markt von USD 15 Milliarden pro Jahr f\u00fcr die ersten wirksamen krankheitsmodifizierenden Behandlungen.<\/p>\n

Die CHF 150’000 von Venture Kick erm\u00f6glichen es dem Unternehmen, seine Kernaktivit\u00e4ten zu etablieren und ein umfassendes In-vitro-Datenpaket zu erstellen, um die einzigartigen Vorteile seiner Technologie zu validieren und potenziellen Investoren und Lizenzpartnern zu demonstrieren.<\/p>\n

Zum Gr\u00fcndungsteam von Amporin geh\u00f6ren CEO Dr. Kelvin Stott, CSO Dr. Herv\u00e9 Schaffhauser und CMO Prof. Daniel Umbricht, die jeweils \u00fcber mehr als 20 Jahre Erfahrung in der Entwicklung von ZNS-Medikamenten und in der Leitung von Forschung und Entwicklung bei mehreren grossen Pharmaunternehmen sowie bei Biotech-Startups verf\u00fcgen.<\/p>\n

„Venture Kick hat uns entscheidend dabei unterst\u00fctzt, ein Weltklasse-Unternehmen mit einer weltver\u00e4ndernden Technologie aufzubauen“, betont Kelvin Stott, Mitgr\u00fcnder und CEO von Amporin Pharmaceuticals. „Ohne Venture Kick h\u00e4tten wir keine M\u00f6glichkeit gehabt, unser Potenzial in die Realit\u00e4t umzusetzen.“<\/p>\n

Quelle: www.venturekick.ch<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Amporin Pharmaceuticals hat von Venture Kick eine Investition von CHF 150’000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren zur Behandlung t\u00f6dlicher degenerativer Erkrankungen voranzutreiben.<\/p>\n","protected":false},"author":380,"featured_media":20150,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3303],"tags":[5551,3327,3352,5549],"class_list":["post-20148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qualitaetsmanagement","tag-investition","tag-qualitaetsmanagement","tag-unternehmen","tag-venture-kick"],"acf":[],"yoast_head":"\nAmporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t<\/title>\n<meta name=\"description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m-q.ch\/de\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta property=\"og:description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m-q.ch\/de\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\" \/>\n<meta property=\"og:site_name\" content=\"MQ Management und Qualit\u00e4t\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ManagementUndQualitaet\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-29T05:48:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"680\" \/>\n\t<meta property=\"og:image:height\" content=\"392\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adelisa Kalajdzini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta name=\"twitter:description\" content=\"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adelisa Kalajdzini\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"author\":{\"name\":\"Adelisa Kalajdzini\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\"},\"headline\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"wordCount\":375,\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"keywords\":[\"Investition\",\"Qualit\u00e4tsmanagement\",\"Unternehmen\",\"Venture Kick\"],\"articleSection\":[\"Qualit\u00e4tsmanagement\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"url\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"description\":\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"width\":680,\"height\":392,\"caption\":\"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Qualit\u00e4tsmanagement\",\"item\":\"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"name\":\"MQ Management und Qualit\u00e4t\",\"description\":\"Plattform f\u00fcr integrierte Managementsysteme.\",\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\",\"name\":\"Galledia Fachmedien AG\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"width\":512,\"height\":512,\"caption\":\"Galledia Fachmedien AG\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ManagementUndQualitaet\",\"https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\",\"name\":\"Adelisa Kalajdzini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"caption\":\"Adelisa Kalajdzini\"},\"url\":\"https:\/\/www.m-q.ch\/de\/author\/adelisa-kalajdzini\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t","description":"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m-q.ch\/de\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","og_locale":"de_DE","og_type":"article","og_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","og_description":"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.","og_url":"https:\/\/www.m-q.ch\/de\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","og_site_name":"MQ Management und Qualit\u00e4t","article_publisher":"https:\/\/www.facebook.com\/ManagementUndQualitaet","article_published_time":"2024-07-29T05:48:13+00:00","og_image":[{"width":680,"height":392,"url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","type":"image\/jpeg"}],"author":"Adelisa Kalajdzini","twitter_card":"summary_large_image","twitter_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","twitter_description":"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.","twitter_image":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","twitter_misc":{"Verfasst von":"Adelisa Kalajdzini","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article","isPartOf":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"author":{"name":"Adelisa Kalajdzini","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175"},"headline":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick","datePublished":"2024-07-29T05:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"wordCount":375,"publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","keywords":["Investition","Qualit\u00e4tsmanagement","Unternehmen","Venture Kick"],"articleSection":["Qualit\u00e4tsmanagement"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","url":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","name":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t","isPartOf":{"@id":"https:\/\/www.m-q.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","datePublished":"2024-07-29T05:48:13+00:00","description":"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.","breadcrumb":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","width":680,"height":392,"caption":"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Qualit\u00e4tsmanagement","item":"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/"},{"@type":"ListItem","position":2,"name":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick"}]},{"@type":"WebSite","@id":"https:\/\/www.m-q.ch\/fr\/#website","url":"https:\/\/www.m-q.ch\/fr\/","name":"MQ Management und Qualit\u00e4t","description":"Plattform f\u00fcr integrierte Managementsysteme.","publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.m-q.ch\/fr\/#organization","name":"Galledia Fachmedien AG","url":"https:\/\/www.m-q.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","width":512,"height":512,"caption":"Galledia Fachmedien AG"},"image":{"@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ManagementUndQualitaet","https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/"]},{"@type":"Person","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175","name":"Adelisa Kalajdzini","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","caption":"Adelisa Kalajdzini"},"url":"https:\/\/www.m-q.ch\/de\/author\/adelisa-kalajdzini\/"}]}},"_links":{"self":[{"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/posts\/20148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/users\/380"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/comments?post=20148"}],"version-history":[{"count":2,"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/posts\/20148\/revisions"}],"predecessor-version":[{"id":20151,"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/posts\/20148\/revisions\/20151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/media\/20150"}],"wp:attachment":[{"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/media?parent=20148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/categories?post=20148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m-q.ch\/de\/wp-json\/wp\/v2\/tags?post=20148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}